EXEL

Exelixis, Inc. | Cotação de Ações

Última atualização31/01/2025, 18:00:02

PreçoUS$ 33,15

Variação (dia)US$ 0,22 (0.67%)▲

Min. 52 SemanasUS$ 20,02

Máx. 52 SemanasUS$ 37,59

Capitalização de mercado--

Endereço: 1851 Harbor Bay Parkway, Alameda, CA, 94502

Telefone: 650 837 7000

Funcionários: 1.310

Exelixis, Inc.EXEL

US$ 33,15

+ 0,220,67%

31/01/2025 18:00:02

1D 7D 1M 3M 1A Tudo

Visão geral da empresa

Preço atualUS$ 33,15

Valor de mercado--

AberturaUS$ 32,81

Preço máximoUS$ 33,65

Preço mínimoUS$ 32,92

VolumeUS$ 2,2 mi

Fechamento anteriorUS$ 32,93

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Ações relacionadas

Incyte Corporation

INCY ▲1.14% | US$ 73,78

BioMarin Pharmaceutical Inc.

BMRN ▲1.34% | US$ 63,14

ACADIA Pharmaceuticals Inc.

ACAD ▲0.35% | US$ 18,62

Sarepta Therapeutics, Inc.

SRPT ▲0.42% | US$ 117,31

Vertex Pharmaceuticals Incorporated

VRTX ▲0.43% | US$ 444,32

Assine nossa newsletter para receber atualizações gratuitas por e-mail

Mantenha-se informado assinando nossa newsletter. Receba atualizações gratuitas por e-mail, incluindo rendimentos, novidades do mercado e insights valiosos. Estamos comprometidos em fornecer informações relevantes diretamente à sua caixa de entrada.

Encontre respostas para suas dúvidas sobre investimentos em nossa seção de Perguntas Frequentes (FAQ)

Acesse a seção de Perguntas Frequentes da brapi para esclarecer dúvidas sobre investimentos. Nossa FAQ fornece informações concisas, abordando tópicos relevantes para investidores, contribuindo para uma compreensão mais clara do mercado financeiro.

Fique por dentro das últimas notícias do mundo financeiro em nosso Blog

Mantenha-se atualizado com as últimas notícias financeiras em nosso Blog. Publicamos artigos informativos e análises de especialistas para fornecer insights valiosos sobre o cenário financeiro em constante evolução.